Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorStanford University
About this trial
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Eligibility criteria
Qualifiers
Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
Able to sign a Stanford IRB approved consent form
Disqualifiers
Refuse or unable to sign an IRB approved consent form.
Refuse to be contacted in the future for follow up.
Trial design
Treatments tested in this trial
- Tumor biopsy
- Phlebotomy
Treatment groups
No treatment groups listed
Sponsors and collaborators
Stanford University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)
Collaborator
Source ClinicalTrials.gov